Clinical Trial Update: Safety and Immunogenicity Study of HIV-MAG Vaccine +/- IL-12 and Ad35-GRIN/ENV in HIV-uninfected Volunteers [Phase 1]

View source ↗

Summary

Phase 1 safety and immunogenicity study of an HIV-MAG vaccine with IL-12 and Ad35-GRIN/ENV in HIV-uninfected volunteers; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Ad35-GRIN/ENV
• HIV-MAG vaccine
• Interleukin-12 (interleukin-12)

Snippet

Sponsor: International AIDS Vaccine Initiative | Conditions: HIV Infections | Phase 1 | Status: COMPLETED